Palatin Technologies

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Palatin Technologies sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Palatin Technologies: 9 sponsored US clinical trials, none currently recruiting.

Palatin Technologies sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoactive Sexual Desire Disorder, with 1 trials.

Top-decile sponsor footprint

Palatin Technologies ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

NCT06565611
ACTIVE NOT RECRUITING Phase 2

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

NCT05466890
COMPLETED Phase 2

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

NCT05709444
COMPLETED Phase 3

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

NCT05201170
TERMINATED Phase 2

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

NCT04318145
COMPLETED Phase 3

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
COMPLETED Phase 3

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02333071
COMPLETED Phase 2

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
COMPLETED Phase 2

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

NCT00425256

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 3

Therapeutic Areas

Hypoactive Sexual Desire Disorder 1
Ulcerative Colitis Flare 1
Ulcerative 1
Ulcerative Colitis Acute 1
Ulcerative Colitis 1
Obesity 1

How the Palatin Technologies early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Hypoactive Sexual Desire Disorder (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Palatin Technologies: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Palatin Technologies4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Palatin Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Palatin Technologies page

9 registered trials is a research-attention snapshot, not an endorsement of Palatin Technologies or any single study.

  • None of Palatin Technologies's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hypoactive Sexual Desire Disorder is the condition Palatin Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoactive Sexual Desire Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Palatin Technologies pipeline card: 9 registered trials from official public datasets.Report a data error.